Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells.
about
Synergistic apoptosis in head and neck squamous cell carcinoma cells by co-inhibition of insulin-like growth factor-1 receptor signaling and compensatory signaling pathways.hMAGEA2 promotes progression of breast cancer by regulating Akt and Erk1/2 pathways.Candidate tumour suppressor CCDC19 regulates miR-184 direct targeting of C-Myc thereby suppressing cell growth in non-small cell lung cancers.Yiqi formula enhances the antitumor effects of erlotinib for treatment of triple-negative breast cancer xenografts.Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.β-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells.Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathwayDual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6Ganoderma lucidum Combined with the EGFR Tyrosine Kinase Inhibitor, Erlotinib Synergize to Reduce Inflammatory Breast Cancer ProgressionmiR-2861 acts as a tumor suppressor via targeting EGFR/AKT2/CCND1 pathway in cervical cancer induced by human papillomavirus virus 16 E6Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-nessAnti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer.Regulatory mechanisms of betacellulin in CXCL8 production from lung cancer cells.Design, synthesis and pharmaco-toxicological assessment of 5-mercapto-1,2,4-triazole derivatives with antibacterial and antiproliferative activitymiRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN.Non-invasive (89)Zr-Transferrin PET Shows Improved Tumor Targeting Compared to (18)F-FDG PET in MYC-overexpressing Human Triple Negative Breast Cancer.Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification.Expression of caveolin-1 is correlated with lung adenocarcinoma proliferation, migration, and invasion.Novel carbazole inhibits phospho-STAT3 through induction of protein-tyrosine phosphatase PTPN6.Interaction of glycosphingolipids GD3 and GD2 with growth factor receptors maintains breast cancer stem cell phenotype.Selective elimination of neuroblastoma cells by synergistic effect of Akt kinase inhibitor and tetrathiomolybdate.Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype.Pro-apoptotic and anti-proliferative effects of mitofusin-2 via PI3K/Akt signaling in breast cancer cells.A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.Caveolin-1 Inhibits Proliferation, Migration, and Invasion of Human Colorectal Cancer Cells by Suppressing Phosphorylation of Epidermal Growth Factor Receptor.BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer.Silence of α1-Antitrypsin Inhibits Migration and Proliferation of Triple Negative Breast Cancer CellsCommunity assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen.
P2860
Q30458494-D3C3F5BA-7CC0-4E5E-83A4-441ED6E69F3EQ33913833-B007DC8E-7950-490C-93B7-F2EC7C4ACA0DQ34311253-8FE2C23E-B557-4CD8-8986-2E3AEF292CE2Q34441761-500AE964-6429-45E6-BEDF-9372ECE20481Q35012485-346D7CDD-5C79-4C3E-A159-543B74412441Q35137658-9E8927A7-A4A6-493E-A621-5092156FF52AQ35578544-9F217E2E-3829-4233-B260-6048319533D4Q35625440-1A523BE2-46EA-4979-8DA3-1473AC4E6E99Q36657315-41DD4CAE-7171-49A4-B952-D449B40B588DQ37057240-AFB500B5-92C7-4DE3-B67D-422E9D30BA09Q37584321-ADDD9054-027F-4CB7-9063-9B3EA857AE7EQ37687445-F7E07D11-02F9-45FE-B257-90CDFC17C279Q37716531-558A30C2-D47D-4920-A4CB-7713F44334ABQ37718697-DCF758D6-124D-4986-8210-8C09603E879DQ37732950-C6512EE0-D263-4401-91F8-5A118D748F85Q38605112-79E612F4-06C7-4CEE-95D7-915734610B6BQ38647802-03558CC3-5AE5-4C45-9D10-188457B7989AQ38861803-64986D1C-B0C9-48FF-A3C1-6F0E5A5BB7A2Q38979718-D100EF02-449C-4C69-BB2D-23D7A9CDB023Q41471118-2D459A12-73BD-4B60-BB31-F8B997538507Q41520294-419B9B4D-DE63-4DF2-BCBF-5CC9EBD3E6F3Q42700663-305BAE48-785A-44C8-8CB8-2B797E82134FQ43148061-6FCA5FD9-D9A4-4A39-8DC7-7CB7F91512F9Q46946333-1E8BBCCA-2961-4C3D-9518-EFD08E04C122Q49704484-DB89A1B6-B20B-46DE-B636-A4DD1ED3012FQ55029136-C53FBA1A-C480-4C52-95F6-7DE64B969CA6Q59127433-40352AC5-69B8-4AA9-A530-81EDC45305B8Q64922122-943be712-4af6-5035-dfa2-25a1d7ac6701
P2860
Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 April 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inhibition of the PI3K/AKT pat ...... -negative breast cancer cells.
@en
Inhibition of the PI3K/AKT pat ...... -negative breast cancer cells.
@nl
type
label
Inhibition of the PI3K/AKT pat ...... -negative breast cancer cells.
@en
Inhibition of the PI3K/AKT pat ...... -negative breast cancer cells.
@nl
prefLabel
Inhibition of the PI3K/AKT pat ...... -negative breast cancer cells.
@en
Inhibition of the PI3K/AKT pat ...... -negative breast cancer cells.
@nl
P2093
P2860
P356
P1476
Inhibition of the PI3K/AKT pat ...... e-negative breast cancer cells
@en
P2093
Antai Wang
Hee Jeong Kim
Hyo Jin Kang
Wenjing Zhao
Wooyoung Hong
Yeon-Sun Seong
P2860
P304
P356
10.1111/JCMM.12046
P50
P577
2013-04-20T00:00:00Z